Developing a 3D B Cell Lymphoma Culture System to Model Antibody Therapy

Diffuse large cell B cell lymphoma (DLBCL) accounts for approximately 30%–40% of all non-Hodgkin lymphoma (NHL) cases. Current first line DLBCL treatment results in long-term remission in more than 60% of cases. However, those patients with primary refractory disease or early relapse exhibit poor pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Foxall, Russell, Narang, Priyanka, Glaysher, Bridget, Hub, Elin, Teal, Emma, Coles, Mark C., Ashton-Key, Margaret, Beers, Stephen A., Cragg, Mark S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897703/
https://www.ncbi.nlm.nih.gov/pubmed/33628205
http://dx.doi.org/10.3389/fimmu.2020.605231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897703/
https://www.ncbi.nlm.nih.gov/pubmed/33628205
http://dx.doi.org/10.3389/fimmu.2020.605231

Ejemplares similares